Patent №
US 7,608,750
Granted
2009-10-27
Filed 2004
Owner
JAPAN SCIENCE AND TECHNOLOGY AGENCY (40%)
+5 more
Lab
—
AI components
2
evo · hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
10496501
The present invention relates to provide a non-human animal model unresponsive to a synthetic compound wherein a gene function encoding TLR7 that recognizes an immunopotentiating synthetic compound such as imidazoquinoline lacks on is genomic locus. Whole or part of a gene fragment of a gene site including an intracellular region and a transmembrane region of a TLR7 gene obtained from a mouse gene library is replaced by a plasmid including poly A signal and a marker gene to construct a targeting vector. Then, this targeting vector is linearized and transferred into embryonic stem cells. The target embryonic stem cells wherein the TLR7 gene function is deleted are microinjected into a mouse blastocyst to generate a chimeric mouse. Then, this chimeric mouse is crossed with a wild-type mouse to generate a heterozygote mouse. Next, the heterozygote mice are intercrossed to obtain a TLR7 knockout mouse.
AI classification
Ownership
JAPAN SCIENCE AND TECHNOLOGY AGENCY (40%)
assignment · 149170351
AKIRA, SHIZUO (40%)
assignment · 149170351
SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (20%)
assignment · 149170351
DAINIPPON SUMITOMO PHARMA CO., LTD. (20%)
merger · 182320368
JAPAN SCIENCE AND TECHNOLOGY AGENCY
assignment · 195820049
DAINIPPON SUMITOMO PHARMA CO., LTD.
assignment · 195820049
Assignors
AKIRA, SHIZUO, TOMIZAWA, HIDEYUKI, YAMAOKA, TAKASHI
On an employer assignment, the assignors are typically the inventors.